Ethypharm - About us - At a glance
At a glance

A clear focus on CNS and Hospital Injectables

Ethypharm is a specialty pharmaceutical company with prominent products in targeted Central Nervous System (CNS) indications, notably severe pain, and opioid dependency as well as a wide range of high-quality injectable medicines for hospitals and emergency situations.

To continue on our transformation journey and accelerate our growth, we have identified specific CNS diseases and conditions and critical care situations where our skills and know-how can be leveraged to bring innovations to patients and health care providers.

Our teams and resources are fully focused on making these opportunities happen.

A resilient company

The COVID-19 pandemic has put significant pressure on the pharmaceutical industry.

At Ethypharm, this pandemic has highlighted the major role of our Hospital Injectable products, which have been in high demand in Intensive Care Units (ICU), as well as our CNS products related to mental health and addictive disorders.

Our manufacturing, quality, supply chain and commercial teams have put in tremendous efforts since the pandemic outbreak to ensure the continuous supply of our medicines in all of our markets.

A committed, diverse, and experienced management team

Ethypharm is about people first. We care deeply about our employees and are proud of the diversity of talents we have internationally.

The Group is led by a management team with a broad range of expertise in the pharmaceutical industry.

An entrepreneurial mindset and shared values knit us together to achieve our vision for the Group.

Discover our Management Team

A solid and growing presence in our core geographies

Since 2015, Ethypharm has built, and is rapidly expanding, its direct commercial presence in Europe and China.

In Europe, Ethypharm is present in the 5 largest markets – Germany, France, Italy, the United Kingdom, and Spain. Direct sales in Europe account for 49% of the Group’s net sales. We are actively working on scaling our presence in these five countries.

In China, Ethypharm is one among the few European specialty pharmaceutical companies to have a longstanding direct presence. This great asset is being leveraged, via partnerships, to bring orphan medicines, that are already registered in other geographies, to patients in China.

And in the rest of the world, we rely on our network of distributors and licensees to establish and develop the reach of our product portfolio.

Ethypharm key figures (2021)

359 M€
Group net sales
in CNS and Hospital Injectables

direct countries

of direct revenues

manufacturing sites